7th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals
24th — 25th February 2015
Lisbon, Portugal
Downloads
Tuesday, February 24, 2015
Advances in the detection and characterization of subvisible and visible particles and other aggregates Andrea Hawe (Coriolis Pharma, Germany)
Pre-existing antibodies to biologics: Predictive for treatment outcome? Claus H. Nielsen (University Hospital Rigshospitalet, Denmark)
Biodistribution of monoclonal antibody aggregates upon SC administration Dr Grzegorz Kijanka (Leiden University, The Netherlands)
Clinical relevance of IFNb Nab in Multiple Sclerosis Florian Deisenhammer (Innsbruck Medical University, Austria)
Wednesday, February 25, 2015
COVA322 case study: development of a novel anti-TNF/IL-17A bispecific FynomAb Bernd Schlereth (Covagen, Switzerland)
Affinity of Anti-Drug Antibodies in human plasma is a potential biomarker for immunogenicity assessment of therapeutic proteins: lessons learned from FVIII replacement therapy Christoph Hofbauer (Baxter BioScience, Austria)
Immunogenicity of RNA therapeutics Katalin Karikó (BioNTech RNA Pharmaceuticals, Germany)
Immuno‐PCR (IPCR) technology for immunogenicity: a comparative study between ECL and Immuno-PCR Laurent Vermet (Sanofi R&D, France)
A Bioactive PK Assay as Surrogate for Detecting Neutralizing Antibodies Matthias Hofmann (Novartis, Switzerland)
Development of a Generic Anti-PEG Antibody Assay Using BioScale's Acoustic Membrane MicroParticle Technology Robert Dodge (Bristol Myers-Squibb, USA)
Aggregation of Human Recombinant Monoclonal Antibodies Enhances Their Presentation by Dendritic Cells In Vitro Sebastian Spindeldreher (Novartis, Switzerland)
A framework for immunogenicity data integration and prediction: Applying mathematical modelling to immunogenicity of biopharmaceuticals Tim Hickling (Pfizer, USA)
